![]() two-dose vaccinees, conditional logistic regression.ĮTable 2. Odds ratios (OR) for SARS-CoV-2 infection, demographics and comorbidities, matched control design, three-dose vaccinees vs. Reduction in the odds of testing positive for SARS-CoV-2 in third-dose vaccinees compared to those who received two doses (marginal effectiveness of the booster), stratified by age group and restricted to those who had received at least one previous test for SARS-CoV-2 in the two months prior to the start of the study (June and July 2021).ĮTable 1. Reduction in the odds of testing positive for SARS-CoV-2 in third-dose vaccinees compared to those who received two doses (marginal effectiveness of the booster), stratified by whether the individual received a negative test for SARS-CoV-2 in the two months prior to the start of the study (June and July 2021).ĮFigure 5. Reduction in the odds of testing positive for SARS-CoV-2 in third-dose vaccinees compared to those who received two doses (marginal effectiveness of the booster), stratified by the presence of comorbidities.ĮFigure 4. Reduction in the odds of testing positive for SARS-CoV-2 in third-dose vaccinees compared to those who received two doses (marginal effectiveness of the booster), stratified by age group.ĮFigure 3. Reduction in the odds of testing positive to SARS-CoV-2 in third-dose vaccinees compared to those who received two doses (marginal effectiveness of the booster).ĮFigure 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |